anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Paragraph

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 118,471
Current window 81,661-81,690
Pages 3,950
Rows per page 30
Component: Paragraphclear collectionreset all
18 30 60

Component

81,661-81,690 of 118,471

filter-aware
167
The slide uses a medical reference to re-frame clinical trial data that was previously dismissed as unrelated.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
172
The slide uses a specific medical case study to establish a pattern of misdiagnosis and severity, linking it to the current subject (pitolisant).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
174
The slide argues that reporting lags or manipulation by Harmony Biosciences obscures the true number of adverse events.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
175
The slide uses a list of adverse events to build a case for cardiotoxicity, highlighting specific fatal and serious outcomes.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
176
The slide highlights specific medical conditions and counts of adverse event reports from the FDA FAERS database.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
177
The slide highlights a potential contradiction between marketing claims of 'no dependency' and reported withdrawal symptoms.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
178
The slide highlights a potential discrepancy between official FDA reporting and actual event timing, suggesting either database lag or manufacturer reporting delays.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
179
The slide uses a 'back-of-the-envelope' calculation to argue that reported adverse events are undercounted.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
182
This is a clinical case report document, likely from an FDA FAERS FOIA request.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
185
The slide presents a narrative summary of a medical case report, pointing out suspicious physician/company behavior regarding the reporting of heart palpitations.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
189
The slide presents a clinical case study analysis of a specific adverse event report (FAERS).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
192
The slide highlights a specific safety concern regarding pitolisant (Wakix) and its interaction with CYP2D6 inhibitors.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
201
The slide presents a patient-reported adverse event (FAERS) to challenge the safety profile of a pharmaceutical product.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
204
The slide highlights a discrepancy between the drug's safety profile as presented and the real-world experience of a physician.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
206
The slide highlights specific clinical symptoms and diagnostic procedures (EKG, cardiac enzymes, telemetry) used to rule out cardiac issues.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
209
The slide uses a table to contrast the clinical trial design with the author's thesis that the evidence standard is too low.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
210
The slide uses a table of clinical trials alongside red-text annotations to highlight the geographic and temporal distance of the studies.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
214
The slide uses excerpts from French regulatory documents to prove the existence and negative results of the unpublished HARMONY 4 trial.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
215
The slide functions as a 'fraud-exposure' or 'villain-critique' framework, systematically dismantling the credibility of the clinical trial data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
217
The slide uses a screenshot of the ESS website to undermine the credibility of the clinical trial endpoint.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
218
The slide uses visual evidence of four different versions of the ESS form to support the claim that the scale lacks a single, consistent format.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
219
The slide uses a 'villain' framing for the Epworth Sleepiness Scale to justify why it should not be used in the context of the research.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
220
The slide uses a critical tone to re-evaluate clinical trial data, highlighting the gap between statistical results and clinical meaningfulness.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
221
The slide uses clinical trial data to undermine the efficacy claims of a drug by highlighting the placebo response.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
222
The slide uses FDA biometrics review data to challenge the efficacy timeline of the drug Wakix (pitolisant).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
223
The author argues that the discrepancy hides a trend reversal that would undermine the trial's efficacy claims.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
226
The slide uses a direct quote from a Lancet letter to undermine the credibility of the HARMONY 1 trial investigators.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
230
The slide uses a redacted document image to illustrate the lack of transparency in the FDA's review process compared to the EMA's.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
232
The slide highlights a discrepancy between raw ESS scores and adjusted LS means, accusing the sponsor of data manipulation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
234
The slide details three specific statistical and methodological reasons for the FDA's rejection of the HARMONY 1 study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit